Table 3.
Credits | Debits |
Long-term survival in 50% of patients | Many patients treated for a few to benefit |
Selection factors have been well defined | The surgical technology is complex and requires an extended learning curve |
An important addition to the MDT for management of colorectal malignancy | Referral by medical oncologist are often late with a large extent of disease |
Morbidity (10%) and mortality (1%) at experienced centers is acceptable | So far a uniform HIPEC treatment has not emerged; perioperative chemotherapy needs to be optimized |
HIPEC: Hyperthermic perioperative chemotherapy.